OGN icon

Organon & Co

12.93 USD
-0.23
1.75%
At close Apr 30, 4:00 PM EDT
After hours
13.08
+0.15
1.16%
1 day
-1.75%
5 days
10.70%
1 month
-13.16%
3 months
-19.04%
6 months
-27.89%
Year to date
-13.57%
1 year
-30.52%
5 years
-65.05%
10 years
-65.05%
 

About: Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Employees: 10,000

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 122 | Existing positions closed: 102

18% more call options, than puts

Call options by funds: $25.5M | Put options by funds: $21.7M

3.02% more ownership

Funds ownership: 76.78% [Q3] → 79.8% (+3.02%) [Q4]

1% more funds holding

Funds holding: 711 [Q3] → 716 (+5) [Q4]

13% less repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 237

17% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 5 (-1) [Q4]

19% less capital invested

Capital invested by funds: $3.78B [Q3] → $3.07B (-$709M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$15
16%
upside
Avg. target
$19.50
51%
upside
High target
$24
86%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Morgan Stanley
Terence Flynn
50% 1-year accuracy
11 / 22 met price target
16%upside
$15
Equal-Weight
Maintained
9 Apr 2025
Barclays
Balaji Prasad
21% 1-year accuracy
9 / 43 met price target
86%upside
$24
Overweight
Maintained
14 Feb 2025

Financial journalist opinion

Based on 13 articles about OGN published over the past 30 days

Positive
Zacks Investment Research
2 days ago
Countdown to Organon (OGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Countdown to Organon (OGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Neutral
Zacks Investment Research
5 days ago
Organon (OGN) Ascends But Remains Behind Market: Some Facts to Note
In the most recent trading session, Organon (OGN) closed at $12.20, indicating a +0.66% shift from the previous trading day.
Organon (OGN) Ascends But Remains Behind Market: Some Facts to Note
Positive
Zacks Investment Research
5 days ago
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Negative
Zacks Investment Research
6 days ago
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
Neutral
Business Wire
2 weeks ago
Organon Appoints Ramona A. Sequeira to the Company's Board of Directors
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.
Organon Appoints Ramona A. Sequeira to the Company's Board of Directors
Neutral
Business Wire
2 weeks ago
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will host Q1 2025 earnings results webcast and conference call on May 1, 2025.
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
Neutral
Zacks Investment Research
2 weeks ago
Organon (OGN) Laps the Stock Market: Here's Why
Organon (OGN) closed the most recent trading day at $11.30, moving +1.07% from the previous trading session.
Organon (OGN) Laps the Stock Market: Here's Why
Positive
Zacks Investment Research
2 weeks ago
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Positive
Zacks Investment Research
2 weeks ago
Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength?
Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength?
Positive
Zacks Investment Research
3 weeks ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Charts implemented using Lightweight Charts™